Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Transl Clin Pharmacol. 2016 Dec;24(4):183-188. English. Original Article. https://doi.org/10.12793/tcp.2016.24.4.183
Son JD , Cho SM , Choi YW , Kim SH , Kwon IS , Jin EH , Kim JW , Hong JH .
Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea. boniii@cnu.ac.kr
Korea United Pharm.Inc., Seoul 06116, Republic of Korea.
Caleb Multilab Inc., Seoul 06745, Republic of Korea.
Clinical Trials Center, Chungnam National University Hospital, Daejeon 35015, South Korea.
Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
Abstract

Cilostazol controlled-release (CR) tablets have recently been developed by Korea United Pharm (Seoul, Korea). The tablets use a patented double CR system, which improves drug compliance by allowing "once daily" administration and reduces adverse events by sustaining a more even plasma concentration for 24 h. We conducted an open, randomized, two-period, two-treatment, crossover study to compare the pharmacokinetic (PK) characteristics and tolerability of cilostazol when administered to healthy Korean male volunteers as CR or immediate release (IR) tablets (Pletal, Korea Otsuka Pharmaceutical Co., Gyeonggi-do, Korea). Each volunteer was randomly allocated to receive a single tablet of cilostazol CR (200 mg) or two tablets of cilostazol IR (100 mg) with a 7-day washout period between treatments. Plasma cilostazol, OPC-13015 (3,4-dehydrocilostazol), and OPC-13213 (4'-trans-hydroxycilostazol) were assayed using liquid chromatography-tandem mass spectrometry for PK analysis. Thirty participants completed the study with no clinically relevant safety issues. The peak concentrations (C(max), mean ± SD) of cilostazol CR and cilostazol IR were 1414.6 ± 49.3 and 1413.1 ± 35.2 ng/mL, respectively, and the areas under the plasma concentration-time curve from 0 to the last concentration (AUC(last)) were 23928.7 ± 65.9 and 25312.0 ± 62.6 ng·h/mL, respectively. The geometric mean ratios (cilostazol CR/cilostazol IR, GMR) of the C(max) and AUC(last) values were 1.001 (90% CI: 0.822, 1.220) and 0.945 (90% CI: 0.814, 1.098), respectively. The frequencies of adverse events were similar. The present study showed that cilostazol PK and tolerability were comparable when administered to healthy Korean men, regardless of whether administered as cilostazol CR or IR.

Copyright © 2019. Korean Association of Medical Journal Editors.